Place of imidazoline receptor agonists in the treatment of arterial hypertension
The review is devoted to one of the most controversial issues of modern antihypertensive therapy — the role of new generation sympatholytics — selective I1-imidazoline receptor agonists (AIRs). In modern European recommendations, AIR (moxonidine rilmenidine), along with other centrally acting drugs...
Saved in:
Main Authors: | D. V. Nebieridze, A. S. Safaryan, E. I. Ivanova, E. A. Poddubskaya |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2023-12-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2943 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Place of imidazoline receptor agonists in the treatment of hypertension
by: D. V. Nebieridze, et al.
Published: (2022-01-01) -
IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES?
by: D. V. Nebieridze, et al.
Published: (2015-12-01) -
Imidazoline receptor agonists: more than blood pressure reduction?
by: D. V. Nebieridze, et al.
Published: (2006-04-01) -
Personalized approach to the treatment of patients with arterial hypertension: focus on imidazoline receptor agonists. Opinion on the problem
by: E. I. Baranova, et al.
Published: (2025-03-01) -
Imidazoline receptor agonists and left ventricular hypertrophy
by: L. L. Kirichenko, et al.
Published: (2005-04-01)